Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309:1696-703. 
Main results
0.40% of children were exposed to antiepileptic drugs during pregnancy; 0.08% were exposed to valproate. 0.83% of children were diagnosed with autism spectrum disorder during follow-up, including 0.32% with childhood autism. Use of valproate during pregnancy was associated with increased risk for autism spectrum disorder and childhood autism in offspring (Table) . Other antiepileptic drugs used as monotherapy during pregnancy were not associated with increased risk for autism spectrum disorder (oxcarbazepine, adjusted hazard ratio [aHR] 2.1, 95% CI 0.96 to 4.6; lamotrigine, aHR 1.7, CI 0.8 to 3.5; clonazepam, aHR 0.7, CI 0.2 to 2.9; carbamazepine, aHR 1.0, CI 0.4 to 2.8) or childhood autism (oxcarbazepine, aHR 1.0, CI 0.1 to 6.9; lamotrigine, aHR 1.7, CI 0.5 to 5.2; clonazepam, aHR 0.9, CI 0.1 to 6.7; carbamazepine, aHR 1.4, CI 0.4 to 5.8) in offspring compared with no use of the specific monotherapy.
Conclusion
Maternal use of valproate during pregnancy was associated with increased risk for autism spectrum disorder and childhood autism in offspring. 
Sources of funding: European

Commentary
The robust observational cohort study by Christensen and colleagues provides timely and relevant information about the association between maternal use of valproate during pregnancy and the occurrence of autism spectrum disorder and childhood autism. Study strengths include long duration of follow-up and careful control of both fetal and parental confounding factors. Potential study limitations include the possibility of selection bias and inability to control for unmeasured confounding factors (1).
When interpreting data on fetal risks associated with maternal valproate use, clinicians should take into account not only the point estimate but also evaluate the upper bounds of the hazard ratio (1). After adjusting for several parental and fetal characteristics, Christensen and colleagues reported a 2.9-fold increased risk for autism spectrum disorder and a 5.2-fold increased risk for childhood autism. The upper bounds of the confidence intervals indicate that 5-fold increases for autism spectrum disorder and 10-fold increases for childhood autism are within the bounds of reasonable probability. These data add weight to evidence in support of a causal association between valproate and child neurodevelopment outcomes (2, 3) .
Faced with such information about potential drug risks, clinicians should carefully consider the benefits of using valproate during pregnancy. Apart from the fetal risks of maternal valproate use identified by Christensen and colleagues, they should also consider risks for relapse of bipolar or seizure disorders and poor pregnancy and fetal outcomes with untreated maternal bipolar disorder or seizures (2), compared with treatment alternatives. Clinicians should also elicit information on the relative importance of these outcomes for their patients and then determine optimal therapy in a shared decision-making context.
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